Marel Q3 2017 results (All amounts in EUR) Q3 2017 –

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
132
Marel Q3 2017 results

(All amounts in EUR)

Q3 2017 – Strong competitive position and good momentum

  • Revenue for Q3 2017 totaled 247.0m [Q3 2016: 234.8m].
  • EBITDA for Q3 2017 was 45.8m or 18.6% of revenue [Q3 2016: EBITDA 41.5m or 17.7% of revenue].
  • EBIT* for Q3 2017 was 37.6m or 15.2% of revenue [Q3 2016: EBIT* 33.4m or 14.2% of revenue].
  • Net result for Q3 2017 was 23.2m [Q3 2016: 17.3m]. Basic earnings per share were 3.29 euro cents in Q3 2017 [Q3 2016: 2.42 euro cents].
  • Cash flow from operating activities before interest and tax in Q3 2017 was 71.8m [Q3 2016: 33.2m]. Net debt/EBITDA was x2.0 at the end of Q3 2017.
  • The order book was at 467.6m at the end of Q3 2017 compared with 418.9m at the end of Q2 2017 [Q3 2016: 305.1m].

In Q3 order intake was robust at 296 million. Market conditions remain good and Marel’s competitive position is strong. The order book was at a good level of 468 million. Revenue in Q3 2017 was 247 million with a solid EBIT* of 15.2%.

Revenue for the first nine months of 2017 was 743 million compared to 733 million on a pro forma basis for the same period in 2016. EBIT* for the first nine months of 2017 was 111 million (15.0% of revenue) compared to 108 million on a pro forma basis for the same period last year (14.8% of revenue). 

Marel’s acquisition of Sulmaq, a Brazilian primary meat processing equipment provider, was finalized on August 31, 2017. Sulmaq’s annual revenue is approximately 25 million. In the short term, the acquisition is not expected to have a material impact on Marel’s financial results.

Cash flow was exceptionally strong in Q3 leading to further deleveraging, despite the acquisition of Sulmaq for an amount equaling the enterprise value of 26 million and the net purchase of treasury shares for 12 million during the quarter. Furthermore Marel continues to invest in the business to stimulate further growth and value creation. Leverage is now down to x2.0 net debt/EBITDA compared to x2.15 in last quarter.

Arni Oddur Thordarson, CEO:

“We are building on good momentum and delivering yet another quarter with robust order intake of 296 million. We are pleased with the operational results in the quarter with 247 million in revenue and EBIT in excess of 15%. 

This is delivered despite softness in the operational results of Marel Meat when compared with previous quarters. The outstanding performance of Marel Poultry in Q3 outweighs this. By being the leading global provider to three industries; poultry, meat and fish, we counterbalance fluctuations in business unit operations, leading to good overall operational results.

Good earnings and strong cash flow enables us to continue to invest in innovation and strengthening the operational platform. In Q3 we finalized the acquisition of Sulmaq in Brazil for 26 millions in addition to acquiring treasury shares for 12 million. Marel´s financial position is strong and net leverage is down to two times EBITDA.

We will continue to engage with new and existing customers around the world in exciting projects that will advance food processing”.  

Markets

Marel’s competitive position is strong and market conditions are good. In Q3, Marel secured record order intake of 296 million. The order book is at an all-time high of 468 million compared with 419 million at the end of Q2 2017 and 305 million at the end of Q3 2016.

Marel is the leading global provider of advanced processing systems and services to the poultry, meat and fish industries. Overall the business is showing good operational performance with a solid 15% EBIT and good underlying market fundamentals. Marel continues to invest in the future to be better equipped to capture market growth and to increase value for its customers and stakeholders.

Revenue streams in poultry and fish are well balanced between standard equipment, Greenfields and maintenance while meat is a more project driven business. Poultry is delivering very strong results throughout this year with good product mix, volume and profitability. The operational performance of Marel Fish is still below long term targets and potential but is on track towards more streamlined and focused organization. Although Meat had a very good first half of the year, timing of delivery of projects adversely affected revenue and operational results in Q3.

Marel Poultry

Marel Poultry had an excellent first nine months (9M) of the year with solid operational profit margins, strong volume and robust order intake. During the first 9M of 2017, Marel Poultry generated 406 million in revenue and 76 million EBIT (18.7% of revenue). Projects were well distributed geographically and between different products. In Q1, a Greenfield project was secured in Russia and in Q2, large orders were secured in Europe and N-America. In Q3, Marel Poultry secured its largest order to-date, a groundbreaking Greenfield project with Costco and Lincoln premium poultry in the U.S. Marel Poultry accounted for 54.6% of Marel’s total revenue for the first 9M of 2017.

Marel Meat

Although Meat had a very good first half of the year, timing of delivery of projects adversely affected revenue and operational results in Q3. During the first 9M of 2017, Marel Meat generated 239 million in revenue and 29 million EBIT* (12.0% of revenue) Marel Meat accounted for 32.1% of Marel’s total revenue during the first 9M. Marel Meat is delivering good projects and fulfilling its customers’ needs worldwide. With the acquisition of Sulmaq in Brazil, Marel is strengthening its position in Central and South America and ensuring better access to a large and growing market for meat building on past sucess in the region in both poultry and fish.

Marel Fish

Marel Fish is on track in Q3 delivering good order intake, and improving operational margins. During the quarter, Marel secured large orders in Norway, S-Africa and Iceland. During the first 9M of 2017, Marel Fish generated 91 million in revenue and 4 million EBIT (3.9% of revenue). Marel Fish accounted for 12.2% of Marel’s total revenue for the first 9M of 2017.

Financial items

Cash flow and investments

The balance sheet is healthy and net interest bearing debt amounted to 375 million at the end of Q3 2017, compared to 443 million at the end of Q3 2016.

Operational cash flow before interest and tax was exceptionally strong at 72 million for Q3 2017 compared to 33 million in Q3 2016. The leverage is down to x2.0 net debt/EBITDA compared to x2.15 last quarter.

Marel continues to invest in the business to prepare for future growth and full potential, which is in line with previous communication. Investment activities are expected to be, on average, above normalized levels for the coming period.

In Q3 2017 Marel acquired Sulmaq where the purchase price is 25.6 million on a debt and cash-free basis.

In Q3 2017, Marel purchased 5.0 million treasury shares for a total amount of EUR 14.5 million to be used as a payment for potential future acquisitions, as per the company’s announcement on February 8, 2017. Marel sold 0.9 million treasury shares for EUR 2.5 million to the management of Sulmaq in relation to Marel‘s acquisition of Sulmaq. The sold shares include a lock-up period of 18 months from the date of closing which was August 31, 2017.

At the end of Q3 2017, Marel had 32.4 million treasury shares (end of Q2 2017: 28.4 million treasury shares).

Outlook

Marel expects market conditions to remain good in the poultry and fish industries, while a softer outlook is expected short term for the meat industry. Long term outlook is good for all industries. Strong position of the order book indicates that revenue will be higher in coming quarters.

Marel is targeting 12% average annual revenue growth in the next 10 years.

  • Marel’s management expects 4-6% average annual market growth in the long term.
  • Marel aims to grow organically faster than the market, driven by innovation and market penetration.
  • Maintaining solid operational performance and strong cash flow supports on average 5-7% revenue growth by acquisition.
  • Marel’s management expects Earnings per Share (EPS) to grow faster than revenue.

Growth will not be linear but based on opportunities and economic fluctuations. Operational results may vary from quarter to quarter due to general economic developments, fluctuations in orders received and timing of deliveries of larger systems.

Marel’s Capital Markets Day 2017

Marel’s Capital Markets Day for institutional investors, analysts and the media will take place on November 2, 2017 at Marel’s demonstration center, Progress Point, in Copenhagen.

Presentation of results, October 26, 2017

Marel will present its results at an investor meeting on Thursday, October 26, 2017 at 8:30 am (GMT), at the company’s headquarters at Austurhraun 9, Gardabaer. The meeting will also be webcasted at marel.com/webcast .

Marel’s Investor calendar 

  • Capital Markets Day in Copenhagen           November 2, 2017
  • 4 th quarter 2017                 February 7, 2018
  • Annual General Meeting    March 6, 2018
  • 1 st quarter 2018                 May 2, 2018
  • 2 nd quarter 2018                July 25, 2018     
  • 3 rd quarter 2018                 October 31, 2018
  • 4 th quarter 2018                 February 6, 2019

Release of financial statements will take place after market closing on the aforementioned dates.

For further information, contact:

Tinna Molphy, Manager in Investor Relations, tel: (+354) 563 8603 / mobile: (+354) 853 8603.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PITAKA Redefines Tech Style With Berlin Launch Event

Updated Category News Views 1

Setting the Stage for Innovation Ah, Berlin in September—a city that’s hardly shy of showcasing avant-garde moves. And this time, we’re not talking about some cryptic art installation or underground techno rave. Nope, it's PITAKA making waves, transforming an edgy display at The Feuerle Collection. You see, on September 5, they unveiled their 'Wind Over Wheat'...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 2

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 1

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading
PureHealth Research Spotlights Simpler Supplement Trends

Updated Category News Views 0

What's Steering the Supplement Ship? Well, if you're paying any attention to the supplement space, you might've noticed something curious: folks are ditching complicated concoctions for good old fashioned simplicity. PureHealth Research, out of Manassas, is throwing the limelight on this trend, where people are handing in their multi-ingredient cocktail for a single...

Continue Reading
LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

Updated Category News Views 0

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Continue Reading
UGREEN's AI Hub: Privacy-First Tech for Smart Homes

Updated Category News Views 1

UGREEN's Big AI Leap In the bustling scene of home tech evolution, UGREEN's throwing its hat in the ring with its latest offerings. They've just rolled out the UGREEN HomeAgent series, aiming to redefine what we think of when it comes to smart living. UGREEN, usually known for its tech gadgets, is diving headfirst into the smart home pool. These local AI hubs blend tech...

Continue Reading
Rho Adds Credit Card Payments to Invoices

Updated Category News Views 2

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...

Continue Reading
York Space Systems Faces Class Action Headwinds

Updated Category News Views 4

York Space Systems: Under Legal Fire You ever hear the one about York Space Systems? Yeah, their ticker YSS is buzzing for all the wrong reasons. Not even a year out from their IPO, and already they're tangled in a class action lawsuit that's got investors with their heads in their hands. ClaimsFiler, a shareholder information outfit, just blasted out a reminder for...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 1

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading

Top 5 Most Recently Viewed Articles

Rover's Insightful Report on Pet Parenthood Cost Trends

Updated Category News Views 209

Understanding the True Cost of Pet Parenthood In their sixth annual report, Rover, a leading online marketplace for pet care, dives deep into the financial aspects of owning pets, highlighting significant trends among pet parents in Canada. This insightful report reveals how pet owners are adapting to a rapidly changing environment, particularly in light of new tariffs...

Continue Reading
Blink Charging Unveils Insights on EV Trends in Live Chat

Updated Category News Views 81

What to Expect from Blink’s Upcoming EV Conversation On September 12 at 10 AM E.T., Brendan Jones and Michael Battaglia will sit down for a live fireside chat—the first such discussion since Blink announced leadership changes planned for 2025. It’s a timely moment to hear directly from the team about how the electric vehicle (EV) landscape is shifting and where...

Continue Reading
MaxLinear's Innovative AI Framework Enhances Wi-Fi for Users

Updated Category News Views 167

MaxLinear Reveals New MaxAI Framework for Enhanced Wi-Fi MaxLinear, Inc. (Nasdaq: MXL), a leader in broadband access technology, has unveiled its revolutionary MaxAI framework. Designed to enhance user experiences and reduce operational costs for Multiple System Operators (MSOs), this native machine learning (ML) technology promises to address the modern challenges faced...

Continue Reading
Breakthrough Publication Highlights Phase 1 Findings of Rhenium-186 Re in Glioblastoma Treatment

Updated Category News Views 138

Exciting Developments in Glioblastoma Treatment Recent advances in the treatment of glioblastoma have emerged, particularly with the promising findings highlighted in a peer-reviewed publication featuring Rhenium-186 Obisbemeda. This innovative approach shows valuable potential for enhancing treatment outcomes for patients suffering from this aggressive form of brain...

Continue Reading
Peter Schiff Warns of Impending Bitcoin and MSTR Collapse

Updated Category News Views 146

Peter Schiff's Bold Predictions for Bitcoin and MSTR Peter Schiff, a prominent financial commentator, has once again made headlines in the cryptocurrency world with his insightful analysis of Bitcoin. His recent statements on social media have raised eyebrows, particularly regarding the future of both Bitcoin and MicroStrategy (NASDAQ: MSTR), a key player in the crypto...

Continue Reading